Prognostic indicators in pituitary tumors

Endocrine Pathology

Volumn 16, Issue 1, 2005, Pages 1-9

  Suhardja, Agustinus ^a   Kovacs, Kalman ^b   Greenberg, Oded ^a   Scheithauer, Bernd W ^c   Lloyd, Ricardo V ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Invasion; Molecular biology; Pathology; Pituitary tumors; Prognosis

Indexed keywords

ANALYTIC METHOD; CELL COMPOSITION; CORRELATION ANALYSIS; COST; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MORPHOLOGY; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 24644514874     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/ep:16:1:001     Document Type: Review

References (60)

1. Castro M, Goverdhana S, Hu J, Jovel N, Yuan X, Lowenstein P. Gene therapy for pituitary tumors: from preclinical models to clinical implementation. Front Neuroendocrinol 24:62-77, 2003.
2. Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 14:25-39, 2003.
3. Levy A, Lightman S. Molecular defects in the pathogenesis of pituitary tumours. Front Neuroendocrinol 24:94-127, 2003.
4. Lloyd RV. Molecular pathology of pituitary adenomas. J Neurooncol 54:111-119, 2001.
5. Farrell WE, Clayton RN. Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10:323-330, 2003.
6. Ezzat S. The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol 11:356-370, 2001.
7. Yamada S, Takada K. Angiogenesis in pituitary adenomas. Microsc Res Tech 60:236-243, 2003.
8. Laws ER, Jane JA Jr. Pituitary tumors - long-term outcomes and expectations. Clin Neurosurg 48:306-319, 2001.
9. Kovacs K, Horvath E. The differential diagnosis of lesions involving the sella turcica. Endocr Pathol 12:389-395, 2001.
10. Kovacs K, Horvath E, Vidal S. Classification of pituitary adenomas. J Neurooncol 54:121-127, 2001.
11. Berg KK, Scheithauer BW, Felix I, et al. Pituitary adenomas that produce adrenocorticotropic hormone and alpha-subunit: clinicopathological, immunohistochemical, ultrastructural, and immunoelectron microscopic studies m nine cases. Neurosurgery 26:397-403, 1990.
12. Iwaki T, Kondo A, Takeshita I, Nakagaki H, Kitamura K, Tateishi J. Proliferating potential of folliculo-stellate cells in human pituitary adenomas. Immunohistochemical and electron microscopic analysis. Acta Neuropathol 71:233-242, 1986.
13. Hucumenoglu S, Kaya H, Kotiloglu E, Erdem G, Demiray E, Ekicioglu G. AgNOR values are not helpful in the differential diagnosis of pituitary adenomas. Clin Neurol Neurosurg 104:293-299, 2002.
14. Pawhkowski M. Immunocytochemical prognostic markers in pituitary tumors. Folia Histochem Cytobiol 39:105-106, 2001.
15. Asa SL. Diseases of the pituitary. Neurosurg Clin N Am 5:71-95, 1994.
16. Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 14:25-39, 2003.
17. Hsu DW, Hakim F, Biller BM, et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753-761, 1993.
18. Thapar K, Yamada Y, Scheithauer B, Kovacs K, Yamada S, Stefaneanu L. Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocr Pathol 7:215-221, 1996.
19. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99-106, 1996.
20. Jin L, Qian X, Kulig E, et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509-519, 1997.
21. Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87:2635-2643, 2002.
22. Blackburn EH. Switching and signaling at the telomere. Cell 106:661-673, 2001.
23. Cabuy E, de Ridder L. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Arch 439:176-184, 2001.
24. Harada K, Arita K, Kurisu K, Tahara H. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation. Surg Neurol 53:267-274, 2000.
25. Yoshino A, Katayama Y, Fukushima T, et al. Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence. J Neurooncol 63:155-162, 2003.
26. Saeger W, Schreiber S, Ludecke DK. Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas. Endocr Pathol 12:39-47, 2001.
27. Vidal S, Kovacs K, Horvath E, et al. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 15:1205-1212, 2002.
28. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 63:2251-2255, 2003.
29. Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85:2931-2935, 2000.
30. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30:3-21, 2000.
31. Vidal S, Kovacs K, Bell D, Horvath E, Scheithauer BW, Lloyd RV. Cyclooxygenase-2 expression in human pituitary tumors. Cancer 97:2814-2821, 2003.
32. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438:595-602, 2001.
33. Szymas J, Schluens K, Liebert W, Petersen I. Genomic instability in pituitary adenomas. Pituitary 5:211-219, 2002.
34. Garcia R, Bueno A, Castanon S, et al. Study of the DNA content by flow cytometry and proliferation in 281 brain tumors. Oncology 54:112-117, 1997.
35. Mork SJ, Laerum OD. Modal DNA content of human intracranial neoplasms studied by flow cytometry. J Neurosurg 53:198-204, 1980.
36. Horvath E, Kovacs K. Pituitary gland. Pathol Res Pract 183:129-142, 1988.
37. Sano T. Use of ultrastructural immunohistochemistry in human pituitary pathology. Microsc Res Tech 20:152-161, 1992.
38. Horvath E, Kovacs K. Ultrastructural diagnosis of human pituitary adenomas. Microsc Res Tech 20:107-135, 1992.
39. Kovacs K, Giannini C, Scheithauer BW, Stefaneanu L, Lloyd RV, Horvath E. Pituitary changes in ataxia-telangiectasia syndrome: an immunocytochemical, in situ hybridization, and DNA cytometric study of three cases. Endocr Pathol 8:195-203, 1997.
40. Yu R, Melmed S. Oncogene activation in pituitary tumors. Brain Pathol 11:328-341, 2001.
41. Ozer E, Canda MS, Ulukus C, Guray M, Erbayraktar S. Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori 89:54-59, 2003.
42. Kulig E, Jin L, Qian X, et al. Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol 154:767-774, 1999.
43. Messini I, Kontogeorgos G, Kovacs K, Horvath E, Smyth HS. Pituitary corticotroph adenoma containing many apoptotic cells: a histologic, immunohistochemical, ultrastructural and molecular study. Ultrastruct Pathol 26:27-32, 2002.
44. Abe T, Tachikawa T, Sasaki A, et al. Histopathological and physiological characteristics of cultured human ACTH-secreting cells derived from a rapidly growing pituitary adenoma. Brain Tumor Pathol 17:133-138, 2000.
45. Yamada S, Asa SL, Kovacs K, Muller P, Smyth HS. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J Clin Endocrinol Metab 68(1):73-80, 1989.
46. Herrmann M. Standard and molecular cytogenetics of endocrine tumors. Am J Clin Pathol 119(Suppl):S17-S38, 2003.
47. Suhardja A, Kovacs K, Rutka J. Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol 52:195-204, 2001.
48. Spada A. Genetic aspects of pituitary tumors. J Pediatr Endocrinol Metab 14(Suppl 5):1213-1216, 2001.
49. Sanno N, Tahara S, Kurotani R, Matsuno A, Teramoto A, Osamura RY. Cytochemical and molecular biological aspects of the pituitary and pituitary adenomas - cell differentiation and transcription factors. Prog Histochem Cytochem 36:263-299, 2001.
50. Evans CO, Reddy P, Brat DJ, et al. Differential expression of folate receptor in pituitary adenomas. Cancer Res 63:4218-4224, 2003.
51. Spada A, Lania A. Genetic changes in human pituitary adenomas. Minerva Endocrinol 28:27-37, 2003.
52. Evans CO, Young AN, Brown MR, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 86:3097-3107, 2001.
53. 11C]-L-deprenyl. Neurosurgery 30:855-861, 1992.
54. Losa M, Mortini P, Barzaghi R, Franzin A, Giovanelli M. Endocrine inactive and gonadotroph adenomas: diagnosis and management. J Neurooncol 54:167-177, 2001.
55. Komori T, Martin WH, Graber AL, Delbeke D. Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature. Clin Nucl Med 27:176-178, 2002.
56. Desiderio DM, Zhan X. The human pituitary proteome: the characterization of differentially expressed proteins in an adenoma compared to a control. Cell Mol Biol 49: 689-712, 2003.
57. Beranova-Giorgianni S, Giorgianni F, Desiderio DM. Analysis of the proteome in the human pituitary. Proteomics 2:534-542, 2002.
58. Beranova-Giorgianni S, Desiderio DM. Mass spectrometry of the human pituitary proteome: identification of selected proteins. Rapid Commun Mass Spectrom 14:161-167, 2000.
59. Zhan X, Desiderio DM. Heterogeneity analysis of the human pituitary proteome. Clin Chem 49:1740-1751, 2003.
60. Zhan X, Desiderio DM. A reference map of a human pituitary adenoma proteome. Proteomics 3:699-713, 2003.